DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/bj6b4t/us_prostate) has announced the addition of the "US Prostate Cancer Drug Pipeline Analysis" report to their offering.
Prostate cancer has emerged as one of the most commonly diagnosed cancer among men in the US. According to the American Cancer Society, there were close to 242,000 new cases of prostate cancer in the US in 2012, with 28,000 men dying from it. This was an increase from 206,640 men diagnosed with the condition during 2009.
The number of men being actively treated for prostrate disorders such as benign prostatic hyperplasia (BPH), prostate cancer, and prostatitis, is on a rise in the recent years. The continuous efforts and investment being directed by the pharmaceutical companies is expected to reduce the incidence rate significantly in the next 5 year horizon.
US Prostate Cancer Drug Pipeline Analysis gives comprehensive insight on the various drugs being developed for the treatment of Prostate Cancer. Research report covers all the ongoing drugs being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Prostate Cancer drug market based upon development process. Following parameters for each drug profile in development phase are covered in US Prostate Cancer Drug Pipeline Analysis research report:
- Drug Profile Overview
- Alternate Names for Drug
- Active Indication
- Phase of Development
- Mechanism of Action
- Brand Name
- Patent Information
- Country for Clinical Trial
- Owner / Originator/ Licensee/Collaborator
- Administrative Route
- Drug Class
- ATC Codes
For more information visit http://www.researchandmarkets.com/research/bj6b4t/us_prostate
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.